SCHEMBL15313372

SCHEMBL15313372

NC(=O)c1cc[n+]([O-])c2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ATM Q13315 2/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 7/20 0.40
ALDH1A1 P00352 4/20 0.40
GAA P10253 1/20 0.40
MAPK14 Q16539 5/20 0.39
MAPT P10636 2/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
PARP1 P09874 1/20 0.37
METAP2 P50579 1/20 0.36
MITF O75030 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
BCAT2 O15382 1/20 0.35
HTT P42858 1/20 0.34
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GLA P06280 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3194423 0.84 NR4A1 (0.46) KMT2AKDM4EALDH1A1MAPK14MAPT
SCHEMBL9332586 0.79 RAB9A (0.47) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL9332576 0.79 KMT2A (0.44) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL28639283 0.71 ATM (0.75) ATMKMT2AKDM4EALDH1A1GAA
SCHEMBL1193736 0.71 IDO1 (0.44) ATMKMT2AKDM4EALDH1A1MAPT
SCHEMBL450730 0.71 CHKA (0.46) KMT2AKDM4EALDH1A1MAPTHPGD
SCHEMBL17145456 0.70 KDM4E (0.40) KMT2AKDM4EALDH1A1GAAMAPT
SCHEMBL6827498 0.69 MAPT (0.38) ATMKDM4EMAPK14MAPTMITF
SCHEMBL633559 0.68 RAB9A (0.36) KDM4EGAAMAPTTSHRMITF
SCHEMBL3367760 0.68 RAB9A (0.61) KMT2AKDM4EALDH1A1MAPK14MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4729067-A2 ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS WITH A SHEET OF ANISOTROPIC MATERIAL Novocure GmbH (CH) 2026-04-22 EP disclosed
EP-4344414-A1 ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL Novocure GmbH (CH) 2024-04-03 EP disclosed
CN-117715678-A Electrode assembly for applying a Tumor Treatment Field (TTFIELD) using an anisotropic sheet of material 诺沃库勒有限责任公司 2024-03-15 CN disclosed
CN-109641864-B Anti-infective agents 邓迪大学 2023-04-04 CN disclosed
US-20230037806-A1 Electrode Assembly for Applying Tumor Treating Fields (TTFields) with a Sheet of Anisotropic Material NOVOCURE GMBH (CH) 2023-02-09 US disclosed
WO-2023012707-A1 ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL NOVOCURE GMBH (CH) 2023-02-09 WO disclosed
US-11485720-B2 Anti-infective agents UNIVERSITY OF DUNDEE (GB) 2022-11-01 US disclosed
EP-3472141-B1 ANTI-INFECTIVE AGENTS UNIV DUNDEE (GB) 2022-10-05 EP disclosed
US-20210101877-A1 ANTI-INFECTIVE AGENTS UNIVERSITY OF DUNDEE (GB) 2021-04-08 US disclosed
US-20190225592-A1 ANTI-INFECTIVE AGENTS UNIVERSITY OF DUNDEE (GB) 2019-07-25 US disclosed
EP-3472141-A1 ANTI-INFECTIVE AGENTS University Of Dundee (GB) 2019-04-24 EP disclosed
WO-2017221002-A1 ANTI-INFECTIVE AGENTS UNIVERSITY OF DUNDEE (GB) 2017-12-28 WO disclosed
EP-2836483-B1 ANTI-MALARIAL AGENTS MERCK PATENT GMBH (DE) 2016-07-27 EP disclosed
US-9115088-B2 Anti-malarial agents MERCK PATENT GMBH (DE) 2015-08-25 US disclosed
EP-2836483-A1 ANTI-MALARIAL AGENTS University Of Dundee (GB) 2015-02-18 EP disclosed
EP-2836483-A1 ANTI-MALARIAL AGENTS University Of Dundee (GB) 2015-02-18 EP disclosed
US-20150045354-A1 Anti-Malarial Agents MERCK PATENT GMBH (DE) 2015-02-12 US disclosed
WO-2013153357-A1 ANTI-MALARIAL AGENTS UNIVERSITY OF DUNDEE (GB) 2013-10-17 WO disclosed
WO-2013153357-A1 ANTI-MALARIAL AGENTS UNIVERSITY OF DUNDEE (GB) 2013-10-17 WO disclosed
CN-1681803-A Aroyl-piperidine derivatives NOVARTIS AG (CH) 2005-10-12 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11485720-B2 Anti-infective agents C1R, RRS1, ARG1 ATM 3574/4885KMT2A 3024/4885KDM4E 2159/4885
US-20150045354-A1 Anti-Malarial Agents PRMT7, MRPS7, RAB7A ATM 4234/4885KMT2A 2494/4885KDM4E 1213/4885
US-20210101877-A1 ANTI-INFECTIVE AGENTS C1R, RRS1, ARG1 ATM 3574/4885KMT2A 3024/4885KDM4E 2159/4885
US-20190225592-A1 ANTI-INFECTIVE AGENTS C1R, ARG1, MSR1 ATM 3612/4885KMT2A 3120/4885KDM4E 2344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.